News
BNGO
--
0.00%
--
Bionano Genomics Announces Study Finds The Combination Of Optical Genome Mapping And Short-Read Sequencing Provides A Comprehensive Genome Analysis For Lung Cancer Samples And Enables The Discovery Of New Biomarkers
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for lung
Benzinga · 3d ago
Study Finds the Combination of Optical Genome Mapping and Short-Read Sequencing Provides a Comprehensive Genome Analysis for Lung Cancer Samples and Enables the Discovery of New Biomarkers
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study finding the combination of optical genome mapping (OGM) and short-read next-generation sequencing (NGS) provides a comprehensive genome analysis for...
GlobeNewswire · 3d ago
Bionano Genomics Announces NuProbe Global Has Adopted Bionano's Saphyr System To Develop Products In Reproductive Health And Oncology Applications
Bionano Genomics, Inc. (NASDAQ:BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano’s Saphyr system for optical genome
Benzinga · 09/07 12:15
NuProbe Global Adopts Bionano’s Saphyr® System to Develop Products in Reproductive Health and Oncology Applications
SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano’s Saphyr sy...
GlobeNewswire · 09/07 12:00
Bionano Genomics Announces ESHG Lineup Featuring 11 Customer Presentations of OGM Data Spanning Three Major Clinical Research Areas of Application from 10 Institutions and Six Countries
SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the European Society of Human Genetics (ESHG) conference lineup featuring 11 customer presentations of optical genome mapping (OGM) data spanning three major...
GlobeNewswire · 08/26 12:00
Inspire Advisors, LLC Buys Inspire Tactical Balanced ESG ETF, Inspire Small/Mid Cap Impact ETF, ...
GuruFocus News · 08/23 15:38
Bionano Stock Will Soar as the Company’s Diagnostic System Catches On
Investor Place · 08/18 10:00
BioNano Genomics Scanning for Commercial Adoption
Biotechnology companies can either be a hit or a miss. If they have yet to commercialize their technology, investing in one can potentially reap lucrative rewards, especially if the company eventually announces successful widespread implementation of its p...
TipRanks · 08/09 14:23
Bionano Genomics posts record quarterly growth while critics point to valuation
Bionano Genomics (NASDAQ:BNGO) jumped over 6% on Thursday after the company reported ~226% YoY revenue growth in Q2 2021, a historical high for a second quarter. After three consecutive quarters of
Seekingalpha · 08/06 15:58
Unusual Options Activity Insight: Bionano Genomics
Bionano Genomics (NASDAQ:BNGO) shares experienced unusual options activity on Friday. The stock price moved down to $6.17 following the option alert.
Benzinga · 08/06 15:20
Faster and Better Clinical Outcomes Make the Case for Bionano Genomics
Investor Place · 08/05 18:26
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/04 22:15
BRIEF-Bionano Genomics Reports Qtrly Revenue $3.9 Mln
reuters.com · 08/04 21:49
Bionano Genomics shares rise on Q2 topline beat
Bionano Genomics (NASDAQ:BNGO) shares rise nearly 4% post market after reporting second-quarter revenue that beat Wall Street estimates, helped by the momentum in the cytogenetics market. The company's chief executive officer Chris Stewart
Seekingalpha · 08/04 20:29
Bionano Genomics beats on revenue
Bionano Genomics (NASDAQ:BNGO): Q2 net loss of $18.8M Revenue of $3.86M (+227.1% Y/Y) beats by $0.34M. Gross margin of 37%, up from 33% in Q1 2021, and down 12% from
Seekingalpha · 08/04 20:09
Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress
226% year-over-year total revenue increase driven by growth in the Saphyr installed baseAll 2021 milestones on trackStrong balance sheet with $333 million in cash as of June 30, 2021Conference call today, Wednesday, August 4, at 4:30 pm ET SAN DIEGO, Aug. ...
GlobeNewswire · 08/04 20:05
Earnings Scheduled For August 4, 2021
  Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Benzinga · 08/04 08:10
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 08/01 14:13
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
Zacks · 07/29 16:51
Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the second quarte...
GlobeNewswire · 07/28 20:30
Webull provides a variety of real-time BNGO stock news. You can receive the latest news about Bionano Genomics through multiple platforms. This information may help you make smarter investment decisions.
About BNGO
Bionano Genomics, Inc. is focused on providing optical genome mapping, solutions for genome analysis. The Company provides tools and services based primarily on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. It also provides diagnostic testing services for pediatric patients suspected of neurodevelopmental disabilities. Its Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to search for diagnostics and therapeutic targets and to streamline the identification of structural changes in chromosomes. The Saphyr system is consists of an instrument, chip consumables, reagents, and a suite of data analysis tools. It also provides proprietary molecular genetic diagnostic services for individuals demonstrating clinical presentations consistent with neurodevelopmental disorders, including autism spectrum disorders and other disorders of childhood development.